echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xinda Bio, in cooperation with Lilly Pharmaceuticals, announced the ORIENT-12 results at ESMO.

    Xinda Bio, in cooperation with Lilly Pharmaceuticals, announced the ORIENT-12 results at ESMO.

    • Last Update: 2020-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ORIENT-12 is the world's first randomized, double-blind, Phase III controlled clinical study for advanced squamous non-small cell lung cancer (sqNSCLC) first-line therapy.
    study included 357 subjects in the group, and in-period analysis showed that Dabershu ® (Syndicate monoantigen injections) combined with exercise ® (injected with gisithamin) and platinum-type contrast placebo combined with placebo ® (injected with giesithamin) and platinum significantly extended progression-free survival (PFS).
    latest analysis showed that the mid-PFS assessed by the Independent Imaging Commission (IRRC) in the Syndicant and Chemotherapy groups was 5.5 months and 4.9 months, respectively (HR=0.536, 95% CI: 0.422-0.681), The researchers assessed the mid-PFS at 6.7 months and 4.9 months (HR-0.532, 95% CI: 0.419-0.674, P.lt; 0.00001), respectively, to reach the preset main study endpoint.
    the medium OS data analyzed in the second phase was premature, and there was a trend of benefit for the total survival of the single-anti-combination group (HR-0.567, 95%CI: 0.353-0.909, P-0.01701).
    safety characteristics are consistent with previously reported ® of the Dabershu ® (Syndili monoantigen injection) and have no new safety signals.
    "Lung cancer is the number one cause of death in all cancers (25.2%), with NSCLC accounting for about 80% to 85%, " said Professor Zhou Caissing, director of oncology at Shanghai Lung Hospital, the lead researcher in the ORIENT-12 study.
    about 70% of NSCLC patients were unable to have surgical removal at the time of diagnosis, and 30-60% of NSCLC patients in phase I-III of genomic surgery eventually relapsed or metastasis.
    the past two decades, NSCLC's drug research and development progress has been mainly concentrated in non-scaly NSCLC, which is relatively slow due to its unique epidemiological, hetological and molecular biology characteristics.
    ORIENT-12 study is the world's first randomized double-blind control study to confirm that anti-PD-1 monoclonal antibodies combined with Gissythabin and platinum can significantly improve the benefits of progression-free survival in patients with first-line scaly NSCLC, which is of clinical significance.
    Health ® (injection with gixiabin) / cisplatin (carpentine) is currently commonly used in Asia's advanced lung squamous cancer standard first-line program, the success of ORIENT-12 research, will benefit more patients with squamous cancer.
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.